Germline TP53 mutations in patients with early-onset colorectal cancer in the Colon Cancer Family Registry

JAMA Oncology

Volumn 1, Issue 2, 2015, Pages 214-221

  Yurgelun, Matthew B ^a,b   Masciari, Serena ^a   Joshi, Victoria A ^c   Mercado, Rowena C ^a   Lindor, Noralane M ^d   Gallinger, Steven ^e   Hopper, John L ^f   Jenkins, Mark A ^f   Buchanan, Daniel D ^f   Newcomb, Polly A ^g   Potter, John D ^g,h,i   Haile, Robert W ^j   Kucherlapati, Raju ^b,c   Syngal, Sapna ^a,b,k  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c LABORATORY FOR MOLECULAR MEDICINE   (United States)

^d MAYO CLINIC   (United States)

^e MOUNT SINAI HOSPITAL   (Canada)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g Fred Hutchinson Cancer Research Center   (United States)

^h UNIVERSITY OF WASHINGTON   (United States)

ⁱ MASSEY UNIVERSITY   (New Zealand)

^j STANFORD CANCER INSTITUTE   (United States)

^k BRIGHAM AND WOMEN S HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DNA GLYCOSYLASE MUTY; DNA GLYCOSYLTRANSFERASE; PROTEIN P53; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AUSTRALIA; BIOLOGICAL MODEL; CANADA; CASE REPORT; CLINICAL TRIAL; COLORECTAL NEOPLASMS; COMPUTER SIMULATION; CROSS-SECTIONAL STUDY; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; GERMLINE MUTATION; HEREDITY; HUMAN; LI-FRAUMENI SYNDROME; MALE; MISMATCH REPAIR; MULTICENTER STUDY; NEW ZEALAND; ONSET AGE; PATHOLOGY; PEDIGREE; PHENOTYPE; PREDICTIVE VALUE; REGISTER; RISK ASSESSMENT; RISK FACTOR; UNITED STATES; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGE OF ONSET; AUSTRALIA; BIOMARKERS, TUMOR; CANADA; COLORECTAL NEOPLASMS; COMPUTER SIMULATION; CROSS-SECTIONAL STUDIES; DNA GLYCOSYLASES; DNA MISMATCH REPAIR; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HEREDITY; HUMANS; LI-FRAUMENI SYNDROME; MALE; MODELS, GENETIC; NEW ZEALAND; PEDIGREE; PHENOTYPE; PREDICTIVE VALUE OF TESTS; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; TUMOR SUPPRESSOR PROTEIN P53; UNITED STATES; YOUNG ADULT;

EID: 84994508622     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.0197     Document Type: Article

References (49)

1. Ahnen DJ, Wade SW, Jones WF, et al. The increasing incidence of young-onset colorectal cancer: a call to action. Mayo Clin Proc. 2014;89(2):216-224.
2. Chang DT, Pai RK, Rybicki LA, et al. Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. Mod Pathol. 2012;25(8):1128-1139.
3. Limburg PJ, Harmsen WS, Chen HH, et al. Prevalence of alterations in DNA mismatch repair genes in patients with young-onset colorectal cancer. Clin Gastroenterol Hepatol. 2011;9(6):497-502.
4. Giráldez MD, Balaguer F, Bujanda L, et al. MSH6 and MUTYH deficiency is a frequent event in early-onset colorectal cancer. Clin Cancer Res.2010;16(22):5402-5413.
5. Stoffel EM, Kastrinos F. Familial colorectal cancer, beyond Lynch syndrome. Clin Gastroenterol Hepatol. 2014;12(7):1059-1068.
6. Wong P, Verselis SJ, Garber JE, et al. Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome. Gastroenterology. 2006;130(1):73-79.
7. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms: a familial syndrome? Ann Intern Med. 1969;71(4):747-752.
8. Li FP, Fraumeni JF Jr, Mulvihill JJ, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988;48(18):5358-5362.
9. Garber JE, Goldstein AM, Kantor AF, Dreyfus MG, Fraumeni JF Jr, Li FP. Follow-up study of twenty-four families with Li-Fraumeni syndrome. Cancer Res. 1991;51(22):6094-6097.
10. Malkin D. Li-fraumeni syndrome. Genes Cancer. 2011;2(4):475-484.
11. Gonzalez KD, Noltner KA, Buzin CH, et al. Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol. 2009;27(8):1250-1256.
12. Masciari S, Dewanwala A, Stoffel EM, et al. Gastric cancer in individuals with Li-Fraumeni syndrome. Genet Med. 2011;13(7):651-657.
13. Chompret A, Abel A, Stoppa-Lyonnet D, et al. Sensitivity and predictive value of criteria for p53 germline mutation screening. J Med Genet. 2001;38(1):43-47.
14. Tinat J, Bougeard G, Baert-Desurmont S, et al. 2009 version of the Chompret criteria for Li Fraumeni syndrome. J Clin Oncol. 2009;27(26):e108-e109.
15. Domchek SM, Bradbury A, Garber JE, Offit K, Robson ME. Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? J Clin Oncol. 2013;31(10):1267-1270.
16. Newcomb PA, Baron J, Cotterchio M, et al; Colon Cancer Family Registry. Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol Biomarkers Prev. 2007;16(11):2331-2343.
17. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007;28(6):622-629.
18. Cleary SP, Cotterchio M, Jenkins MA, et al. Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study. Gastroenterology. 2009;136(4):1251-1260.
19. Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res. 2001;11(5):863-874.
20. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248-249.
21. Exome Variant Server NGESPE, Seattle WA. http://evs.gs.washington.edu/EVS/. Accessed May 2, 2014.
22. Dickens DS, Dothage JA, Heideman RL, Ballard ET, Jubinsky PT. Successful treatment of an unresectable choroid plexus carcinoma in a patient with Li-Fraumeni syndrome. J Pediatr Hematol Oncol. 2005;27(1):46-49.
23. Tabori U, Nanda S, Druker H, Lees J, Malkin D. Younger age of cancer initiation is associated with shorter telomere length in Li-Fraumeni syndrome. Cancer Res. 2007;67(4):1415-1418.
24. Varley JM, McGown G, Thorncroft M, et al. Are there low-penetrance TP53 alleles? evidence from childhood adrenocortical tumors. Am J Hum Genet. 1999;65(4):995-1006.
25. Wagner J, Portwine C, Rabin K, Leclerc JM, Narod SA, Malkin D. High frequency of germline p53 mutations in childhood adrenocortical cancer. J Natl Cancer Inst. 1994;86(22):1707-1710.
26. Hayes VM, Dirven CM, Dam A, et al. High frequency of TP53 mutations in juvenile pilocytic astrocytomas indicates role of TP53 in the development of these tumors. Brain Pathol. 1999;9(3):463-467.
27. Pinto C, Veiga I, Pinheiro M, et al. TP53 germline mutations in Portugal and genetic modifiers of age at cancer onset. Fam Cancer. 2009;8(4):383-390.
28. Arcand SL, Maugard CM, Ghadirian P, et al. Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families. Breast Cancer Res Treat. 2008;108(3):399-408.
29. Quesnel S, Verselis S, Portwine C, et al. p53 compound heterozygosity in a severely affected child with Li-Fraumeni syndrome. Oncogene. 1999;18(27):3970-3978.
30. Manoukian S, Peissel B, Pensotti V, et al. Germline mutations of TP53 and BRCA2 genes in breast cancer/sarcoma families. Eur J Cancer.2007;43(3):601-606.
31. Keller G, Vogelsang H, Becker I, et al. Germline mutations of the E-cadherin (CDH1) and TP53 genes, rather than of RUNX3 and HPP1, contribute to genetic predisposition in German gastric cancer patients. J Med Genet.2004;41(6):e89.
32. Melhem-Bertrandt A, Bojadzieva J, Ready KJ, et al. Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer. 2012;118(4):908-913.
33. Mitchell G, Ballinger ML, Wong S, et al; International Sarcoma Kindred Study. High frequency of germline TP53 mutations in a prospective adult-onset sarcoma cohort. PLoS One. 2013;8(7):e69026.
34. Pekova S, Mazal O, Cmejla R, et al. A comprehensive study of TP53 mutations in chronic lymphocytic leukemia: analysis of 1287 diagnostic and 1148 follow-up CLL samples. Leuk Res. 2011;35(7):889-898.
35. Diller L, Sexsmith E, Gottlieb A, Li FP, Malkin D. Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. J Clin Invest. 1995;95(4):1606-1611.
36. Cornelis RS, van Vliet M, van de Vijver MJ, et al. Three germline mutations in the TP53 gene. Hum Mutat. 1997;9(2):157-163.
37. Huusko P, Castrén K, Launonen V, et al. Germ-line TP53 mutations in Finnish cancer families exhibiting features of the Li-Fraumeni syndrome and negative for BRCA1 and BRCA2. Cancer Genet Cytogenet. 1999;112(1):9-14.
38. van Hest LP, Ruijs MW, Wagner A, et al. Two TP53 germline mutations in a classical Li-Fraumeni syndrome family. Fam Cancer. 2007;6(3):311-316.
39. Jasperson KW, Vu TM, Schwab AL, et al. Evaluating Lynch syndrome in very early onset colorectal cancer probands without apparent polyposis. Fam Cancer. 2010;9(2):99-107.
40. Mouchawar J, Korch C, Byers T, et al. Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study. Cancer Res. 2010;70(12):4795-4800.
41. Lalloo F, Varley J, Moran A, et al. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. Eur J Cancer. 2006;42(8):1143-1150.
42. Stadler ZK, Schrader KA, Vijai J, Robson ME, Offit K. Cancer genomics and inherited risk. J Clin Oncol. 2014;32(7):687-698.
43. Gonzalez KD, Buzin CH, Noltner KA, et al. High frequency of de novo mutations in Li-Fraumeni syndrome. J Med Genet. 2009;46(10):689-693.
44. Bougeard G, Sesboüé R, Baert-Desurmont S, et al; French LFS Working Group. Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet. 2008;45(8):535-538.
45. Olivier M, Goldgar DE, Sodha N, et al. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res. 2003;63(20):6643-6650.
46. Masciari S, Van den Abbeele AD, Diller LR, et al. F18-fluorodeoxyglucose-positron emission tomography/computed tomography screening in Li-Fraumeni syndrome. JAMA. 2008;299(11):1315-1319.
47. Wijnen J, Khan PM, Vasen H, et al. Majority of hMLH1 mutations responsible for hereditary nonpolyposis colorectal cancer cluster at the exonic region 15-16. Am J Hum Genet. 1996;58(2):300-307.
48. Grover S, Kastrinos F, Steyerberg EW, et al. Prevalence and phenotypes of APC and MUTYH mutations in patients with multiple colorectal adenomas. JAMA. 2012;308(5):485-492.
49. Moreira L, Balaguer F, Lindor N, et al; EPICOLON Consortium. Identification of Lynch syndrome among patients with colorectal cancer. JAMA. 2012;308(15):1555-1565.